DKK/RUB Price & Performance (DKKRUB)

West Pharmaceutical Services continues to struggle, with shares down 38.2% after disappointing full-year guidance for FY25. The stock remains below key moving averages, reflecting bearish sentiment. Despite these challenges, analysts maintain a 'Strong Buy' rating, citing a potential 29.2% price upside. Competitive pressures and currency headwinds remain key concerns.1

U.S. stock futures fell sharply amid fears of tariffs and economic slowdown. The Nasdaq led declines with a 1.8% drop, while Tesla, Nvidia, and other major tech firms saw notable losses. Treasury yields also dropped as investor sentiment soured. The S&P 500 recorded its worst weekly performance in six months.2

Novo Nordisk's shares have plummeted nearly 50% from 2024 highs after its obesity drug CagriSema failed to outperform existing treatments in key trials. Investors remain skeptical about its potential to dominate the market, with upcoming trials in 2026 seen as the company's opportunity to regain confidence.3